Effects of Topical Cream for Pain Relief
Document Magnitude and Timing for Pain Relief of Topical Cream
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Klamath Falls, Oregon, United States, 97601-5904
- Gitte Jensen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI between 18.5 and 34.9 kg/m2 (inclusive)
- Chronic joint/muscle related pain for at least past 6 months
- Experiencing chronic pain in at least one specific anatomical area for more than 6 months.
Exclusion Criteria:
- Cancer during past 12 months
- Chemotherapy during past 12 months
- Currently taking prescription pain medications
- Getting regular joint injections (such as cortisone shots);
- Immunization during last month
- Participation in another clinical trial study during this trial, involving an investigational product or lifestyle change
- Regularly experiencing headaches, including migraines
- Serious active illness within past 6 months
- Significant active uncontrolled illness (such as lymphoma, liver disease, kidney failure, heart failure).
- Skin allergies related to ingredients in test product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Topical cream, 1 - 2 times daily
Application of a pea-sized amount of cream applied to skin over the area with chronic pain
|
Topical cream applied to painful joint or muscle
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in degree of pain
Time Frame: 4 weeks
|
Pain questionnaire - yes/no, score 0-24 hours
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Activity level
Time Frame: 4 weeks
|
Activities of daily living questionnaire
|
4 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wellness
Time Frame: 4 weeks
|
Wellness questionnaire - Score 0-10 [0 being strongly disagree, 10 being strongly agree]
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 173-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.